3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasm Metastasis
10
Lung Neoplasms
9
Carcinoma, Medullary
9
Neoplasms
6
Thyroid Neoplasms
5
Glioma
5
Glioblastoma
5
Gliosarcoma
4
Colorectal Neoplasms
4
Brain Neoplasms
4
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Familial medullary thyroid carcinoma
2
Disease Progression
2
Colonic Neoplasms
2
Carcinoma, Squamous Cell
2
Biliary Tract Neoplasms
2
Waldenstrom Macroglobulinemia
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Interventions
midostaurin
2
vandetanib
1
selinexor
1
pegfilgrastim
1
Topotecan
1
Rituximab
1
Prednisone
1
Paclitaxel
1
Methylprednisolone
1
Immunologic Techniques
1
Ifosfamide
1
Flow Cytometry
1
Etoposide
1
Dexamethasone
1
Clofarabine
1
Carboplatin
1
Bexarotene
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Aggression
×
vandetanib
×
Clear all
NCT01945762
2024-12-18
Caprelsa104
Sanofi
Completed
31 enrolled